Giovanna Bossi

Abingdon, ENG, United Kingdom

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 12 publications

Beta cell-targeted PD-1 agonist inhibits cell-mediated autoimmunity in pancreas tissue slices.

Beta cell-targeted PD-1 agonist inhibits cell-mediated autoimmunity in pancreas tissue slices.

Journal: Science advances

Published: April 01, 2026

Inhibition of cell-mediated immunity in type 1 diabetes by beta cell-targeted PD-1 agonists in pancreas tissue slices.

Inhibition of cell-mediated immunity in type 1 diabetes by beta cell-targeted PD-1 agonists in pancreas tissue slices.

Journal: bioRxiv : the preprint server for biology

Published: November 24, 2025

Cell-targeted PD-1 agonists are potent NK-cell inhibitors.

Cell-targeted PD-1 agonists are potent NK-cell inhibitors.

Journal: Frontiers in immunology

Published: June 03, 2025

Enhanced target-specific delivery of docetaxel-loaded nanoparticles using engineered T cell receptors.

Enhanced target-specific delivery of docetaxel-loaded nanoparticles using engineered T cell receptors.

Journal: Nanoscale

Published: September 17, 2021

Cell-targeted PD-1 agonists that mimic PD-L1 are potent T cell inhibitors.

Cell-targeted PD-1 agonists that mimic PD-L1 are potent T cell inhibitors.

Journal: JCI insight

Published: June 18, 2021

An approved in vitro approach to preclinical safety and efficacy evaluation of engineered T cell receptor anti-CD3 bispecific (ImmTAC) molecules.

An approved in vitro approach to preclinical safety and efficacy evaluation of engineered T cell receptor anti-CD3 bispecific (ImmTAC) molecules.

Journal: PloS one

Published: May 17, 2018

Polyfunctional response by ImmTAC (IMCgp100) redirected CD8+ and CD4+ T cells.

Polyfunctional response by ImmTAC (IMCgp100) redirected CD8+ and CD4+ T cells.

Journal: Immunology

Published: January 18, 2017

Elimination of Latently HIV-infected Cells from Antiretroviral Therapy-suppressed Subjects by Engineered Immune-mobilizing T-cell Receptors.

Elimination of Latently HIV-infected Cells from Antiretroviral Therapy-suppressed Subjects by Engineered Immune-mobilizing T-cell Receptors.

Journal: Molecular therapy : the journal of the American Society of Gene Therapy

Published: November 03, 2015

Direct molecular mimicry enables off-target cardiovascular toxicity by an enhanced affinity TCR designed for cancer immunotherapy.

Direct molecular mimicry enables off-target cardiovascular toxicity by an enhanced affinity TCR designed for cancer immunotherapy.

Journal: Scientific reports

Published: September 30, 2015

Examining the presentation of tumor-associated antigens on peptide-pulsed T2 cells.

Examining the presentation of tumor-associated antigens on peptide-pulsed T2 cells.

Journal: Oncoimmunology

Published: September 16, 2013

Identification of a Titin-derived HLA-A1-presented peptide as a cross-reactive target for engineered MAGE A3-directed T cells.

Identification of a Titin-derived HLA-A1-presented peptide as a cross-reactive target for engineered MAGE A3-directed T cells.

Journal: Science translational medicine

Published: August 09, 2013

ImmTAC-redirected tumour cell killing induces and potentiates antigen cross-presentation by dendritic cells.

ImmTAC-redirected tumour cell killing induces and potentiates antigen cross-presentation by dendritic cells.

Journal: Cancer immunology, immunotherapy : CII

Published: April 19, 2013

Showing 1-12 of 12

Last Updated: 09/26/2026